AR132329A1 - Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos - Google Patents
Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estosInfo
- Publication number
- AR132329A1 AR132329A1 ARP240100843A ARP240100843A AR132329A1 AR 132329 A1 AR132329 A1 AR 132329A1 AR P240100843 A ARP240100843 A AR P240100843A AR P240100843 A ARP240100843 A AR P240100843A AR 132329 A1 AR132329 A1 AR 132329A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- propionic acid
- tautomers
- acceptable salts
- substituted indazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Derivados de ácido indazol propiónico sustituidos, sales aceptables desde el punto de vista farmacéutico, tautómeros o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos que pueden activar la proteína quinasa activada por adenosina 5-monofosfato (AMPK). Además, composiciones farmacéuticas que comprenden derivados de ácido indazol propiónico sustituidos activadores de AMPK, sales aceptables desde el punto de vista farmacéutico, tautómeros o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos y al menos un excipiente aceptable desde el punto de vista farmacéutico, y métodos para tratar una afección que comprende administrar derivados de ácido indazol propiónico sustituidos activadores de AMPK, sales aceptables desde el punto de vista farmacéutico, tautómeros, o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363494598P | 2023-04-06 | 2023-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132329A1 true AR132329A1 (es) | 2025-06-18 |
Family
ID=90721385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100843A AR132329A1 (es) | 2023-04-06 | 2024-04-05 | Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240336572A1 (es) |
| EP (1) | EP4688750A1 (es) |
| JP (1) | JP2026515644A (es) |
| KR (1) | KR20250164854A (es) |
| CN (1) | CN121039104A (es) |
| AR (1) | AR132329A1 (es) |
| AU (1) | AU2024249981A1 (es) |
| CO (1) | CO2025013813A2 (es) |
| CR (1) | CR20250419A (es) |
| DO (1) | DOP2025000253A (es) |
| IL (1) | IL323522A (es) |
| MX (1) | MX2025011902A (es) |
| PE (1) | PE20260010A1 (es) |
| TW (1) | TWI899933B (es) |
| WO (1) | WO2024209363A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024209363A1 (en) * | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| WO2026074467A1 (en) * | 2024-10-04 | 2026-04-09 | Pfizer Inc. | Extended release formulations comprising substituted indazole propionic acid derivative compounds and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0578850A1 (en) | 1992-07-17 | 1994-01-19 | Biogal Gyogyszergyar | Process for the preparation of carboxylic acids and derivatives of them |
| ES2546815T3 (es) | 2006-12-15 | 2015-09-28 | Bristol-Myers Squibb Company | Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa |
| EP2235004A4 (en) | 2007-12-21 | 2011-05-04 | Univ Health Network | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT |
| EP2242757B1 (en) | 2008-01-09 | 2012-08-01 | Array Biopharma, Inc. | Pyrazolopyridines as kinase inhibitors |
| WO2009149837A1 (en) | 2008-06-09 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof |
| CA2767233A1 (en) | 2009-07-14 | 2011-01-20 | Albany Molecular Research, Inc. | 5-ht3 receptor modulators, methods of making, and use thereof |
| EP2993169B1 (en) | 2009-11-17 | 2017-12-20 | Novartis AG | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
| TWI516262B (zh) | 2010-04-06 | 2016-01-11 | 健康網路大學 | 激酶抑制劑及以其治療癌症的方法 |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| WO2012119046A2 (en) | 2011-03-02 | 2012-09-07 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| EP2694509B1 (en) | 2011-04-05 | 2016-05-18 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases |
| EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
| WO2013030138A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| US8889730B2 (en) * | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2014049133A1 (en) | 2012-09-28 | 2014-04-03 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
| JP6441830B2 (ja) | 2013-03-14 | 2018-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンcの置換2−アザ−ビシクロ[2.2.1]ヘプタン−3−カルボン酸(シアノ−メチル)−アミド阻害剤 |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| WO2016004305A2 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| KR20160030001A (ko) | 2014-09-05 | 2016-03-16 | 삼성디스플레이 주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| CA2969164A1 (en) | 2014-12-23 | 2016-06-30 | Genfit | Heterocyclic derivatives as rorgamma modulators |
| WO2016115360A1 (en) | 2015-01-14 | 2016-07-21 | Coferon, Inc. | C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same |
| CN108299425B (zh) | 2015-03-24 | 2020-09-18 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| WO2016161571A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| WO2018229543A2 (en) | 2017-06-14 | 2018-12-20 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| MX2020006168A (es) | 2017-12-18 | 2020-08-13 | Bristol Myers Squibb Co | Compuestos de 4-azaindol. |
| CN112020496B (zh) | 2018-04-18 | 2023-04-28 | 南京明德新药研发有限公司 | 作为rho激酶抑制剂的苯并吡唑类化合物 |
| EP3787612A4 (en) | 2018-05-04 | 2021-11-17 | Remedy Plan, Inc. | CANCER TREATMENTS AGAINST CANCER STEM CELLS |
| EP3813784B1 (en) | 2018-06-07 | 2024-01-10 | The Regents Of The University Of Michigan | Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith |
| JP7511564B2 (ja) * | 2018-12-31 | 2024-07-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリア機能不全を治療する方法及び配合物 |
| CN113453753B (zh) | 2019-02-06 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| KR102873783B1 (ko) | 2019-02-25 | 2025-10-21 | 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 | Jak 억제제 화합물 및 그 사용 |
| MX2022014505A (es) * | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| JP2023553835A (ja) | 2020-12-17 | 2023-12-26 | ブロッサムヒル・セラピューティクス・インコーポレイテッド | 大環状化合物およびそれらの使用 |
| WO2022150574A1 (en) | 2021-01-08 | 2022-07-14 | Cornell University | Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase |
| WO2022204150A1 (en) | 2021-03-22 | 2022-09-29 | Blue Oak Pharmaceuticals, Inc. | Compounds and compositions for treating cns disorders |
| TW202304890A (zh) | 2021-04-14 | 2023-02-01 | 美商百歐克斯製藥公司 | Klk5雙環雜芳香族抑制劑 |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| WO2023091707A1 (en) | 2021-11-19 | 2023-05-25 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of jak and methods of use |
| CN119013256A (zh) * | 2022-01-25 | 2024-11-22 | Evvia治疗公司 | Ampk激动剂及其使用方法 |
| EP4504722A4 (en) | 2022-04-04 | 2026-03-18 | Brenig Therapeutics Inc | LRRK2 INHIBITORS |
| WO2024209363A1 (en) * | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
-
2024
- 2024-04-03 WO PCT/IB2024/053239 patent/WO2024209363A1/en not_active Ceased
- 2024-04-03 CN CN202480023808.3A patent/CN121039104A/zh active Pending
- 2024-04-03 EP EP24718603.4A patent/EP4688750A1/en active Pending
- 2024-04-03 PE PE2025002225A patent/PE20260010A1/es unknown
- 2024-04-03 TW TW113112725A patent/TWI899933B/zh active
- 2024-04-03 AU AU2024249981A patent/AU2024249981A1/en active Pending
- 2024-04-03 KR KR1020257036972A patent/KR20250164854A/ko active Pending
- 2024-04-03 CR CR20250419A patent/CR20250419A/es unknown
- 2024-04-03 JP JP2025557975A patent/JP2026515644A/ja active Pending
- 2024-04-04 US US18/626,467 patent/US20240336572A1/en active Pending
- 2024-04-05 AR ARP240100843A patent/AR132329A1/es unknown
-
2025
- 2025-09-22 IL IL323522A patent/IL323522A/en unknown
- 2025-10-03 MX MX2025011902A patent/MX2025011902A/es unknown
- 2025-10-06 CO CONC2025/0013813A patent/CO2025013813A2/es unknown
- 2025-10-06 DO DO2025000253A patent/DOP2025000253A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024249981A1 (en) | 2025-10-16 |
| EP4688750A1 (en) | 2026-02-11 |
| TWI899933B (zh) | 2025-10-01 |
| CN121039104A (zh) | 2025-11-28 |
| CO2025013813A2 (es) | 2025-10-20 |
| US20240336572A1 (en) | 2024-10-10 |
| CR20250419A (es) | 2025-10-07 |
| TW202448861A (zh) | 2024-12-16 |
| IL323522A (en) | 2025-11-01 |
| MX2025011902A (es) | 2025-11-03 |
| KR20250164854A (ko) | 2025-11-25 |
| JP2026515644A (ja) | 2026-05-19 |
| DOP2025000253A (es) | 2025-11-30 |
| PE20260010A1 (es) | 2026-01-06 |
| WO2024209363A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2025000253A (es) | Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos | |
| CR20220558A (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| DOP2022000234A (es) | Compuestos útiles para inhibir la quinasa ret | |
| NO20053775L (no) | Diazepinoindol derivater som kinaseinhibitorer. | |
| UY31027A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol | |
| DOP2024000209A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| AR131639A1 (es) | Inhibidores de kif18a y usos de los mismos | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| DK1622610T3 (da) | 1-(2H-pyrazol-3-yl)-3-{4-[1-[benzoyl)-piperidin-4-ylmethyl]-penyl}-urinstofderivater og beslægtede forbindelser som inhibitorer af p38-kinase og/eller TNF-inhibitorer til behandlingen af inflammationer | |
| AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
| AR020688A1 (es) | Derivados de la imidazo [4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones f | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| AR132983A1 (es) | Inhibidores keap1 y usos de los mismos | |
| CL2022000889A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| MX2024010321A (es) | Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos | |
| MX2025001493A (es) | Inhibidores de cinasa dependiente de ciclina (cdk) 12 y/o cdk13 y usos de los mismos | |
| AR024476A1 (es) | Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen. | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| GT200500020A (es) | Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa. | |
| CO2025010159A2 (es) | Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo | |
| AR133286A1 (es) | Inhibidores ra2s heterocíclicos de igf-1r para el tratamiento de enfermedades | |
| AR062545A1 (es) | Formulaciones estables de quinolinonas |